Lisata Therapeutics Secures U.S. Patent for Certepetide

Lisata Therapeutics ( (LSTA) ) has shared an update.

On July 15, 2025, Lisata Therapeutics announced that it received a U.S. patent for certepetide, covering its chemical structure and pharmacokinetic properties, which will extend protection until March 2040. This patent strengthens Lisata’s intellectual property portfolio, granting exclusive rights to certepetide and enhancing its market position by delaying generic competition, thereby increasing potential growth and value for shareholders.

The most recent analyst rating on (LSTA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.

Spark’s Take on LSTA Stock

According to Spark, TipRanks’ AI Analyst, LSTA is a Neutral.

Lisata Therapeutics is navigating through financial difficulties with persistent losses and negative cash flows. The stock’s technical indicators and valuation reflect a challenging financial position. However, recent advancements in clinical trials and regulatory achievements offer potential upside, albeit with high risk.

To see Spark’s full report on LSTA stock, click here.

More about Lisata Therapeutics

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company is known for its cyclic peptide product candidate, certepetide, which is designed to enhance the delivery and effectiveness of anti-cancer drugs in solid tumors. Lisata has established significant commercial and research partnerships and is actively pursuing the development of its CendR Platform® technology.

Average Trading Volume: 16,341

Technical Sentiment Signal: Sell

Current Market Cap: $23.3M

For an in-depth examination of LSTA stock, go to TipRanks’ Overview page.